Physician

Christopher Gene Wang, M.D

According to 2025 Medicare claims, Christopher Wang, M.D (NPI: 1083856157) practices medical oncology in the Birmingham, AL market, with the plurality of this provider's patient population coming from Jefferson, AL. This provider's primary affiliated billing organization is BIRMINGHAM HEMATOLOGY ONCOLOGY ASSOC LLC (NPI: 1841216389; TIN: 522170293) and primary practice location at 35243-3509.

Wang's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 606 traditional Medicare patients, billed 129,434 HCPCS/CPT codes, and received $2,617,603 in Medicare payments. The top billing code was 99213 (Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more). Part D data shows 2,119 prescription claims across 285 beneficiaries totaling $5,652,838 in drug costs, led by Revlimid (Lenalidomide). DME data shows 11 claims. Open Payments data shows 189 records totaling $8,610. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $101,649 to $2,617,603. Similarly, Part D prescription costs have moved sharply higher in recent years, from $2,900 to $5,652,838. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	134	5,069	$101,649
2016	254	49,779	$675,400
2017	320	37,376	$506,979
2018	282	86,201	$677,272
2019	412	150,898	$1,427,472
2020	438	229,397	$3,112,977
2021	472	170,841	$2,322,699
2022	540	193,239	$2,703,966
2023	601	147,385	$2,352,134
2024	606	129,434	$2,617,603

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	23	45	$2,900
2016	77	635	$434,555
2017	105	877	$853,970
2018	134	1,053	$1,143,038
2019	183	1,201	$1,456,556
2020	203	1,681	$1,908,204
2021	227	1,887	$2,635,214
2022	298	2,391	$4,720,765
2023	283	2,299	$5,700,591
2024	285	2,119	$5,652,838

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	66	$8,838
2019	N/R	64	$7,161
2020	N/R	12	$1,241
2021	N/R	78	$3,442
2022	N/R	27	$713
2023	N/R	N/R	N/R
2024	N/R	11	$524

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	171	308	$59
88184	Flow cytometry technique for dna or cell analysis, first marker	159	187	$50
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	160	273	$12
36415	Insertion of needle into vein for collection of blood sample	410	1,191	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	376	1,066	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	90	2,226	$1,220,526
Calquence	Acalabrutinib Maleate	51	1,530	$745,802
Lenalidomide	Lenalidomide	61	1,386	$567,354
Pomalyst	Pomalidomide	17	476	$382,589
Ibrance	Palbociclib	18	504	$279,711

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	11	$524

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	186	$3,557	ABBVIE INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	3	$5,054	AstraZeneca UK Limited
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Christopher Gene Wang, M.D?

Tedicare shows public-source Medicare data for Christopher Gene Wang, M.D (NPI 1083856157), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Christopher Gene Wang, M.D have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Christopher Gene Wang, M.D?

Christopher Gene Wang, M.D is linked to BIRMINGHAM HEMATOLOGY ONCOLOGY ASSOC LLC (billing NPI 1841216389) in the available physician profile data.

Does Christopher Gene Wang, M.D have Open Payments data?

Christopher Gene Wang, M.D has 189 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.